Overcoming challenges in the life sciences industry
As the life sciences industry works, invests and collaborates tirelessly to fast-track testing and treatment for COVID-19, they must also continue to advance their pipelines and rethink ways of bringing treatments to patients- people depend on it.
Empowering life sciences teams to collaborate and work remotely is paramount. In addition, managing supply chain challenges so basic materials can get to clinical trials and patients and ensuring quality and safety in manufacturing is essential.
The COVID-19 pandemic is not just a short-term crisis. It has long-lasting implications for how people work, how we will treat patients and how companies will operate and be viewed in the world. Life sciences companies can redefine their position on the world stage and set a new standard as trusted, valued partners in the healthcare community.
Lead with integrity and trust
Perhaps more than ever before, the integrity and trust in life sciences companies is on a global stage. It's a once in a generation chance to do things differently.
In this climate of crisis, your responses and actions determine both how you lead in the near-term and how you can pave the way for future progress. Leaders will seize this time to take swift action and proactively prepare the organization to continue to manage its core business while ensuring a continued focus on patient health and treating COVID-19.
As you prepare and plan your response, we'd like to share our latest thinking on how the industry could manage the human and business impact.
What we learned
Accenture surveyed patients and healthcare providers (HCPs) to gauge the impact coronavirus has had on their treatments, care and operations.
of patients want to use technology more for communicating with healthcare providers and managing their conditions.
of patients used new devices or apps to help manage conditions remotely during COVID-19.
of HCPs saw a decrease in the number of patients visiting their practice during COVID-19.
What we think
We asked 720 healthcare providers (HCPs) globally on how operations and needs changed during COVID-19 and the effects for patients and pharmas.
Our life sciences leaders weigh in on the impact COVID-19 has had across all aspects of the industry and how we can take the lessons into the new challenges ahead.